Saurabh Saha, Centessa CEO (BIO19/Endpoints News)
Centessa axes lead program after a patient in kidney disease safety study is hospitalized
Less than four months after dosing the first patients in a pivotal study for its lead program, Centessa is instead reversing course in a big …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
